Tempus AI, Inc. announced the clinical launch of the ArteraAI Prostate Test (mHSPC). This specialized ArteraAI Prostate Test (mHSPC) provides urologists and oncologists with an advanced digital pathology solution. The prognostic framework integrates fully into the Tempus platform. It directly helps inform the personalization of therapy intensity. The tool assists individuals facing metastatic hormone-sensitive prostate cancer.
This algorithm marks the first externally developed digital pathology test within the Tempus diagnostics ecosystem. The test evaluates clinical information and histopathology biopsy images. It calculates a personalized risk estimate of prostate cancer-specific mortality. This insight targets a significant diagnostic gap. Approximately 25,000 patients receive a new metastatic prostate cancer diagnosis in the United States each year.
Advanced Algorithmic Insights for Precision Medicine
Clinicians can order the ArteraAI Prostate Test (mHSPC) as an add-on. It connects seamlessly with the solid tumor portfolio across all ordering modalities. The system combines genomic-based next-generation sequencing assay results with pathology-based AI findings. This synthesis delivers a comprehensive assessment of advanced disease.
Artera developed the platform using multimodal artificial intelligence. The technology leverages digitized histopathology images and clinical data. This workflow determines cancer aggressiveness and predicts treatment benefits. Multiple Phase 3 randomized trials across different cancers validated the methodology. Artera maintains its headquarters in Los Altos, California, and runs a clinical laboratory in Jacksonville, Florida.
“From the start of our Tempus collaboration, our goal has been to deliver Artera’s AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way,” said Amanda Lowe, Chief Commercial Officer at Artera. “We’re excited that the newest product line extension of our ArteraAI Prostate Test, designed specifically for metastatic hormone-sensitive prostate cancer patients, will now be easily accessible throughout the Tempus ecosystem.”
“Our mission is to bring actionable, data-driven insights directly to the point of care so clinicians can make more confident treatment decisions,” said Laura Elster, Chief Commercial Officer of Diagnostics at Tempus. “By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy, helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
